Clinical Trials Logo

Filter by:
NCT ID: NCT04921553 Recruiting - Cancer Clinical Trials

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

TRacKING
Start date: June 22, 2021
Phase:
Study type: Observational [Patient Registry]

This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion. This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications.

NCT ID: NCT04920591 Completed - Dementia Clinical Trials

Doll Therapy in Dementia

DESCRIBE
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Behavioral and psychologic symptoms in dementia (BPSD) are frequent and represent a burden for patients and caregivers, the use of a first line non-pharmacologic approach is highly recommended. DESCRIBE is a randomized controlled trial on the effect of doll therapy (DT) on BPSD in different clinical settings. The investigators will enroll fifty-two nursing homes residents and 52 acute in-patients with dementia and BPSD. Subjects will be randomized to DT or standard treatment (ST), The investigators will measured agitation, delirium and caregiver burden with standard clinical scales at baseline and during treatment. Nursing home residents will be evaluated after 45 and 90 days of treatment, in-patients will be evaluated at baseline and at hospital discharge. In acute in-patients, a follow-up of 4 weeks after hospital discharge will be carried out in order to evaluate the effect of DT withdrawal. Primary outcomes will be the reduction of BPSD and the reduction of professional caregiver burden Secondary outcome will be the reduction of delirium and of effect of family caregiver burden.

NCT ID: NCT04920149 Recruiting - Colon Cancer Clinical Trials

Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome

MesaCAPP
Start date: March 21, 2022
Phase: Phase 2
Study type: Interventional

Multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with 2000mg mesalamine, or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients during and following daily intake for 2 years.

NCT ID: NCT04919850 Completed - Obesity Clinical Trials

Effect of 60-days Saccharomyces Boulardii and Superoxide Dismutase Supplementation in Obese Adults

Start date: January 15, 2018
Phase: N/A
Study type: Interventional

In animals it has been demonstrated that Saccharomyces boulardii decrease low-grade inflammation and fat mass; also Superoxide Dismutase (SOD) decrease low-grade inflammation. Therefore, the aim of this double-blind, placebo-controlled clinical trial was to assess the effect of a 60-days S. boulardii and SOD supplementation on circulating markers of inflammation, body composition, hunger sensation, pro/antioxidant ratio, hormonal, lipid profile, glucose, insulin and HOMA-IR, in obese adults (BMI 30-35 kg/m2).

NCT ID: NCT04919811 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

TRUST-II
Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.

NCT ID: NCT04919512 Recruiting - Clinical trials for Urinary Bladder Neoplasms

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

SunRISe-4
Start date: July 7, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.

NCT ID: NCT04919226 Recruiting - Clinical trials for Neuroendocrine Tumors

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

COMPOSE
Start date: December 21, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy, safety & patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.

NCT ID: NCT04918173 Recruiting - Clinical trials for Congenital Antithrombin Deficiency

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

Start date: July 1, 2022
Phase: Phase 3
Study type: Interventional

Assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under cover of Atenativ for surgical procedures or parturition.

NCT ID: NCT04917991 Completed - Healthy Diet Clinical Trials

Comparison Between Olive Oil and Palm Oil-enricHed chOCOlate Spreads (CHOCO) in Healthy Subjects

CHOCO
Start date: May 2, 2019
Phase: N/A
Study type: Interventional

This clinical trial aims to investigate if extra virgin olive oil (EVOO) or palm oil enriched chocolate spread snacks consumption lead to differential insulin resistance status in young, healthy subjects. Such effect includes difference in a) plasma ceramides, b) glucose metabolism markers, c) lipid profile, d) inflammatory markers, e) hunger/satiety hormonal markers and visual analogue scale.

NCT ID: NCT04917757 Active, not recruiting - Clinical trials for Adrenal Incidentaloma

Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas

NAPACA
Start date: January 1, 2015
Phase:
Study type: Observational [Patient Registry]

The primary aim of the study is to assess mortality and cardiovascular events potentially linked to cortisol excess in patients with adrenal incidentalomas stratified by cortisol values following the 1-mg overnight dexamethasone test.